Any feedback?
Literature summary for 1.14.14.1 extracted from
- Effects of Andrographis paniculata extract and Andrographolide on hepatic cytochrome P450 mRNA expression and monooxygenase activities after in vivo administration to rats and in vitro in rat and human hepatocyte cultures (2009), Chem. Biol. Interact., 179, 247-255.
Localization
| Localization | Comment | Organism | GeneOntology No. | Textmining |
|---|---|---|---|---|
| microsome | - |
Homo sapiens | - |
- |
| microsome | - |
Rattus norvegicus | - |
- |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Homo sapiens | - |
- |
- |
| Homo sapiens | P05177 | - |
- |
| Rattus norvegicus | P04799 | - |
- |
| Rattus norvegicus | P04800 | - |
- |
| Rattus norvegicus | P05182 | - |
- |
| Rattus norvegicus | P08683 | - |
- |
Source Tissue
| Source Tissue | Comment | Organism | Textmining |
|---|---|---|---|
| hepatocyte | - |
Homo sapiens | - |
| hepatocyte | - |
Rattus norvegicus | - |
Substrates and Products (Substrate)
| Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
|---|---|---|---|---|---|---|
| 6beta-hydroxytestosterone + [reduced NADPH-hemoprotein reductase] + O2 | - |
Rattus norvegicus | ? | - |
? |  |
| 7-ethoxyresorufin + [reduced NADPH-hemoprotein reductase] + O2 | - |
Homo sapiens | ? | - |
? | |
| 7-ethoxyresorufin + [reduced NADPH-hemoprotein reductase] + O2 | - |
Rattus norvegicus | ? | - |
? | |
| p-nitrophenol + [reduced NADPH-hemoprotein reductase] + O2 | - |
Rattus norvegicus | ? | - |
? | |
| p-nitrophenol + [reduced NADPH-hemoprotein reductase] + O2 | CYP2E1 | Homo sapiens | ? | - |
? | |
| testosterone + [reduced NADPH-hemoprotein reductase] + O2 | CYP3A4 | Homo sapiens | 6beta-hydroxytestosterone + [oxidized NADPH-hemoprotein reductase] + H2O | - |
? | |
| tolbutamide + [reduced NADPH-hemoprotein reductase] + O2 | - |
Rattus norvegicus | ? | - |
? | |
| tolbutamide + [reduced NADPH-hemoprotein reductase] + O2 | CYP2C9 | Homo sapiens | ? | - |
? | |
Synonyms
| Synonyms | Comment | Organism |
|---|---|---|
| CYP1A2 | - |
Homo sapiens |
| CYP1A2 | - |
Rattus norvegicus |
| CYP2C11 | - |
Rattus norvegicus |
| CYP2C9 | - |
Homo sapiens |
| CYP2E1 | - |
Homo sapiens |
| CYP2E1 | - |
Rattus norvegicus |
| CYP3A1 | - |
Rattus norvegicus |
| CYP3A4 | - |
Homo sapiens |
Cofactor
| Cofactor | Comment | Organism | Structure |
|---|---|---|---|
| NADPH | - |
Homo sapiens | |
Expression
| Organism | Comment | Expression |
|---|---|---|
| Rattus norvegicus | in hepatocyte cultures, treated with 0.05 mM Andrographis paniculata extract and Andrographolide, CYP2E1 is not significantly decreased (by 30%) | down |
| Rattus norvegicus | in hepatocyte cultures, treatment with 0.05 mM Andrographis paniculata extract and Andrographolide results in a 50% decrease in CYP3A1 expression and activity | down |
| Rattus norvegicus | in hepatocyte cultures, treatment with 0.05 mM Andrographis paniculata extract and Andrographolide results in a 60% decrease in CYP1A2 expression and activity | down |
| Rattus norvegicus | in hepatocyte cultures, treatment with 0.05 mM Andrographis paniculata extract and Andrographolide results in a 60% decrease in CYP2C11 expression and activity. After in vivo administration, Andrographis paniculata extract at dose levels of 0.5 g/kg/day (i.e. 5 mg/kg/day Andrographolide equivalents) and at 2.5 g/kg/day (i.e. 25 mg/kg/day Andrographolide equivalents) and Andrographolide at dose levels of 5 and 25 mg/kg/day significantly decrease CYP2C11 activity | down |
| Homo sapiens | in hepatocyte cultures, treatment with 0.05 mM Andrographis paniculata extract results in a slight decrease of CYP1A2 (30%) enzymatic activities | down |
| Homo sapiens | in hepatocyte cultures, treatment with 0.05 mM Andrographis paniculata extract results in a slight decrease of CYP2E1 (20%) enzymatic activities, whereas CYP2C9- and CYP3A4-dependent monooxygenase activities are significantly decreased by 40% and 60%, respectively. Andrographolide causes a 30% decrease in CYP2C9- and CYP3A4-dependent monooxygenase activities, which is not significant | down |
| Rattus norvegicus | beta-naphthoflavone (0.05 mM) causes a 71fold increase in CYP1A2-dependent activity and a 253fold increase in CYP1A2 mRNA expression in hepatocyte microsomes | up |
| Homo sapiens | beta-naphthoflavone (0.05 mM) causes a 9fold increase in CYP1A2-dependent activity and a 25fold increase in CYP1A2 mRNA expression in hepatocyte microsomes | up |
| Rattus norvegicus | dexamethasone (0.05 mM) and rifampicin (0.01 mM) increase CYP2C11 activity by a mean of 1.4fold in hepatocytes | up |
| Homo sapiens | dexamethasone (0.05 mM) and rifampicin (0.01 mM) increase CYP3A4 mRNA expression by a mean of 14fold in hepatocytes | up |
| Rattus norvegicus | dexamethasone (0.05 mM) increases CYP3A1 activity by a mean of 6fold and dexamethasone (0.05 mM) and rifampicin (0.01 mM) increase CYP3A1 mRNA expression by a mean of 167fold in hepatocytes | up |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
